UB Paderborn / Katalog / Suche / in CDI

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Journal of clinical oncology, 2013-01, Vol.31 (1), p.23-29

2013

Volltextzugriff (PDF)

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Journal of clinical oncology, 2000-05, Vol.18 (10), p.2095-2103

2000

Volltextzugriff (PDF)

Proposal for size justification of expanded cohort at phase-2-recommended dose

Investigational new drugs, 2011-08, Vol.29 (4), p.713-715

2011

Volltextzugriff (PDF)

α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel

Clinical cancer research, 2003-03, Vol.9 (3), p.1077-1082

2003

Volltextzugriff (PDF)

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

Radiation oncology (London, England), 2011-09, Vol.6 (1), p.124-124, Article 124

2011

Volltextzugriff (PDF)

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Journal of clinical oncology, 2023-05, Vol.41 (15), p.2673-2681

2023

Volltextzugriff (PDF)

Results of the GYNECO 02 Study, an FNCLCC Phase III Trial Comparing Hysterectomy with No Hysterectomy in Patients with a (Clinical and Radiological) Complete Response After Chemoradiation Therapy for Stage IB2 or II Cervical Cancer

The oncologist (Dayton, Ohio), 2012-01, Vol.17 (1), p.64-71

2012

Volltextzugriff (PDF)

A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310)

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.252-252

2012

Volltextzugriff (PDF)

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2000-03, Vol.27 (3), p.145-157

2000

Volltextzugriff (PDF)

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial

Journal of clinical oncology, 2012-06, Vol.30 (18_suppl), p.LBA4003-LBA4003

2012

Volltextzugriff (PDF)

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.LBA4003-LBA4003

2012

Volltextzugriff (PDF)

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Anti-cancer drugs, 2000-01, Vol.11 (1), p.7-13

2000

Volltextzugriff (PDF)

Fotemustine in the Treatment of Brain Primary Tumors and Metastases

Cancer investigation, 1994, Vol.12 (4), p.414-420

1994

Volltextzugriff (PDF)

Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma

Cancer chemotherapy and pharmacology, 1993, Vol.32 (4), p.329-331

1993

Volltextzugriff (PDF)

Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Bulletin du cancer, 2005-01, Vol.92 (1), p.E1

2005

Volltextzugriff (PDF)

Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer

European journal of cancer (1990), 1993, Vol.29 (2), p.288-289

1993

Volltextzugriff (PDF)

Phase II study of pirarubicin in advanced non-small cell lung cancer

European journal of cancer & clinical oncology, 1989-09, Vol.25 (9), p.1337-1338

1989

Volltextzugriff (PDF)

Phase II study of pirarubicin in advanced non-small cell lung cancer

European journal of cancer & clinical oncology, 1989-10, Vol.25 (10), p.1507-1508

1989

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: The French randomised trial ACCORD12/0405 PRODIGE 2

Proposal for size justification of expanded cohort at phase-2-recommended dose

α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Results of the GYNECO 02 Study, an FNCLCC Phase III Trial Comparing Hysterectomy with No Hysterectomy in Patients with a (Clinical and Radiological) Complete Response After Chemoradiation Therapy for Stage IB2 or II Cervical Cancer

A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310)

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: The French randomised trial ACCORD 12/0405 PRODIGE 2

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Fotemustine in the Treatment of Brain Primary Tumors and Metastases

Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma

Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer

Phase II study of pirarubicin in advanced non-small cell lung cancer

Phase II study of pirarubicin in advanced non-small cell lung cancer

Suchergebnisse filtern